摘要
目的观察稳肾颗粒对脾肾两虚浊瘀互结型慢性肾功能衰竭患者的临床疗效及安全性。方法选择2016年1月—2018年1月该院肾内科住院和门诊随访的脾肾两虚、浊瘀互结型CKD1-3期的慢性肾衰竭患者80例,随机分为治疗组和对照组,各40例,在西医治疗的基础上,治疗组给予稳肾颗粒口服,对照组给予百令胶囊口服,观察患者治疗前后的血红蛋白、尿素氮、血肌酐、肾小球滤过率及中医症状积分的变化;监测血常规、肝肾功能、心电图等安全性指标及稳肾颗粒对脾肾两虚浊瘀互结型慢性肾功能衰竭患者的临床疗效及安全性。结果治疗组总有效率83%,明显高于对照组的有效率56%(χ~2=7.040,P=0.008)。中医证候积分疗效:两组证候积分较治疗前均明显降低(对照组t=2.214,P=0.033;治疗组t=6.454,P=0.000),而治疗组明显优于对照组(t=4.624,P=0.000)。两组的血清肌酐、肾小球滤过率水平水平均较治疗前好转(对照组肌酐t=2.042,P=0.048;治疗组肌酐t=3.826,P=0.000;对照组eGFR t=2.962,P=0.021;治疗组e GFR t=6.379,P=0.017),治疗组疗效明显优于对照组(肌酐t=2.214,P=0.033;e GFR t=9.275,P=0.005),两组的尿素氮、血红蛋白均较治疗前好转(对照组尿素氮t=2.594,P=0.043;治疗组尿素氮t=3.632,P=0.010;对照组血红蛋白t=6.382,P=0.023;治疗组血红蛋白t=7.224,P=0.001),但两组间差异无统计学意义(尿素氮t=0.209,P=0.417;血红蛋白t=0.720,P=0.237)。结论稳肾颗粒治疗脾肾两虚浊瘀互结型慢性肾功能衰竭疗效满意,无严重不良反应,值得临床大力推广。
Objective To observe the clinical efficacy and safety of Wenshen Granule in patients with chronic kidney failure caused by spleen and kidney deficiency. Methods Eighty patients with chronic renal failure of CKD1-3 with spleen and kidney deficiency and phlegm and blood stasis type were enrolled in the Department of Nephrology during January 2016 to January 2018. They were randomly divided into treatment group and control group, 40 cases in each case. On the basis of Western medicine treatment, the treatment group was given wenshen granules orally, and the control group was given Bailing Capsules orally. The changes of hemoglobin, urea nitrogen, serum creatinine, glomerular filtration rate and TCM symptom scores before and after treatment were observed. Conventional, liver and kidney function, electrocardiogram and other safety indicators and the clinical efficacy and safety of Wenshen Granule in patients with chronic kidney failure caused by spleen and kidney deficiency. Results The total effective rate of the treatment group was 83%, which was significantly higher than that of the control group 56%(χ^2=7.040, P=0.008). Efficacy of TCM syndrome scores: the scores of syndromes in both groups were significantly lower than those before treatment (control group t=2.214, P=0.033;treatment group t=6.454, P=0.000), while the treatment group was significantly better than the control group (t= 4.624, P=0.000). Serum creatinine and glomerular filtration rate levels were better in the two groups than in the control group (control group creatinine t=2.042, P=0.048;treatment group creatinine t=3.826, P=0.000;control group eGFR t=2.962, P=0.021;treatment group eGFR t=6.379, P=0.017), the treatment group was significantly better than the control group (creatinine t=2.214, P=0.033;eGFR t=9.275, P=0.005), the two groups of urea nitrogen, hemoglobin were better than before treatment (control group urea nitrogen t=2.594, P=0.043;treatment group urea nitrogen t=3.632, P=0.010;control group hemoglobin t=6.382, P=0.023;treatment group hemoglobin t=7.224, P= 0.001), but there was no significant difference between the two groups (urea nitrogen t=0.209, P= 0.417;hemoglobin t=0.720, P= 0.237). Conclusion Wenshen Granule is effective in the treatment of chronic renal failure caused by spleen and kidney deficiency and phlegm and blood stasis. There is no serious adverse reaction, which is worthy of clinical promotion.
作者
朱莺
魏晴雪
张航
ZHU Ying;WEI Qing-xue;ZHANG Hang(Department of Nephrology, Changshu Traditional Chinese Medicine Hospital, Changshu,Jiangsu Province, 215500 China)
出处
《世界复合医学》
2019年第1期1-4,11,共5页
World Journal of Complex Medicine
基金
江苏省中医药局科技项目立项计划资助课题(LZ13158)
关键词
稳肾颗粒
慢性肾衰竭
脾肾两虚浊瘀互结型
Wenshen granule
Chronic renal failure
Spleen and kidney deficiency
